Drawing for BIDOSINE

USPTO serial 77257135

BIDOSINE

Reviewed by CopyMark Law Group

Reg. 3898369Status 710
Filing date
Status date
Registration date
Jan 4, 2011
Examiner
EISINGER, REBECCA MILES
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with BIDOSINE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew Roppel

ANDREW ROPPEL HOLLAND & HART LLPPO BOX 8749ATTN. MICHELE CLARKDENVER, CO 80201

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for treating cardiovascular diseases, namely, ischemic heart diseases, cardiac insufficiency, hypertension, arrhythmias, thrombosis, atherosclerosis, peripheral arterial disease, restenosis, and shock resuscitation; pharmaceutical preparations for treating cerebral diseases, namely, stroke, brain ischemia and spinal cord ischemia; pharmaceutical preparations for treating inflammatory diseases associated to organ ischemia pathologies; pharmaceutical preparations for treating angiogenesis; pharmaceutical preparations for treating pulmonary diseases, namely, pulmonary hypertension; pharmaceutical preparations for the diagnosis of ischemia, namely, myocardial ischemiaSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 11, 2017C8..CANCELLED SEC. 8 (6-YR)—
Jan 4, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 19, 2010NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 19, 2010PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 13, 2010PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 7, 2010CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 2, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 2, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 30, 2010ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
May 9, 2010GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
May 9, 2010GNSLLETTER OF SUSPENSION E-MAILED—
May 9, 2010CNSLSUSPENSION LETTER WRITTEN—
May 7, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 7, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 3, 2010ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Nov 5, 2009GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Nov 5, 2009GNSIINQUIRY TO SUSPENSION E-MAILED—
Nov 5, 2009CNSISUSPENSION INQUIRY WRITTEN—
Nov 4, 2009RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Nov 4, 2009ALIEASSIGNED TO LIE—
Apr 30, 2009GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Apr 30, 2009GNSLLETTER OF SUSPENSION E-MAILED—
Apr 30, 2009CNSLSUSPENSION LETTER WRITTEN—
Apr 30, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 30, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 28, 2009ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 28, 2008GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Oct 28, 2008GNSIINQUIRY TO SUSPENSION E-MAILED—
Oct 28, 2008CNSISUSPENSION INQUIRY WRITTEN—
Oct 23, 2008RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Oct 23, 2008ALIEASSIGNED TO LIE—
Apr 23, 2008GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Apr 23, 2008GNSLLETTER OF SUSPENSION E-MAILED—
Apr 23, 2008CNSLSUSPENSION LETTER WRITTEN—
Apr 22, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 22, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 22, 2008TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 28, 2007GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 28, 2007GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 28, 2007CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 26, 2007DOCKASSIGNED TO EXAMINER—
Aug 21, 2007NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance